Acute lymphoblastic leukemia (ALL) is an aggressive blood and bone marrow cancer in which too many lymphocytes or lymphoblasts are produced. The disease progresses quickly without treatment and can involve both marrow and peripheral blood.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
New research addresses CAR T-cell therapy safety through a venetoclax-controlled on-off switch and a prospective study identifying neurotoxicity risk markers in pediatric patients with acute lymphoblastic leukemia.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07584889 |
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT07575412 |
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07572136 |
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07562568 |
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07515430 |
The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia |
ENROLLING_BY_INVITATION | |
| NCT07499349 |
Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia |
RECRUITING | |
| NCT07498465 |
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia |
WITHDRAWN | PHASE1 |
| NCT07483749 |
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors |
NOT_YET_RECRUITING | |
| NCT07479927 |
Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy |
RECRUITING | NA |
